Neurocrine Biosciences Announced The Presentation Of New Analysis From Phase 3, Open-Label Kinect 4 Study, Which Showed Clinically Meaningful Improvement In Tardive Dyskinesia Symptoms With Once-Daily Dose Of 40 Mg INGREZZA Capsules For 48 Weeks

Author: Benzinga Newsdesk | October 17, 2025 08:37am

• Continuous treatment with INGREZZA 40 mg for 48 weeks resulted in sustained, clinically meaningful improvements in tardive dyskinesia symptoms
• 90% of participants who completed 48 weeks of continuous treatment with INGREZZA 40 mg achieved a ≥50% improvement in the Abnormal Involuntary Movement Scale Total Score
• INGREZZA is the only vesicular monoamine transporter 2 (VMAT2) inhibitor that allows patients to start immediately at a therapeutic dose without required titration

SAN DIEGO, Oct. 17, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of a new post-hoc analysis from the Phase 3, open-label KINECT® 4 study, demonstrating that patients treated continuously for 48 weeks with the 40 mg dose of once-daily INGREZZA® (valbenazine) capsules experienced clinically meaningful improvements in tardive dyskinesia symptoms. Findings will be presented at the American Psychiatric Nurses Association 39th Annual Conference, taking place October 15-18 in New Orleans.

The KINECT 4 Phase 3, open-label study evaluated the long-term efficacy, safety and tolerability of INGREZZA in adults with tardive dyskinesia (TD). Participants in the post-hoc analysis received INGREZZA 40 mg once daily for the first four weeks, with the option to escalate to 80 mg daily at Week 4, based on tolerability and clinical response. From Week 4 through Week 48, dose reduction from 80 mg to 40 mg was permitted based on individual tolerability.

Posted In: AREC